Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea
Executive Summary
Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.
You may also be interested in...
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
AbbVie Expected To Ditch Abicipar After US FDA Setback
With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.
Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.